Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy2件: Bezafibrate,
Ursodeoxycholic acid (UDCA)		2件: Ursodiol ,
Bezafibrate 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94 💬
2Bezafibrate 200 MG IN addition TO udca therapy2件: Bezafibrate,
Ursodeoxycholic acid (UDCA)		2件: Ursodiol ,
Bezafibrate 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
3Bezafibrate 400 MG IN addition TO udca therapy2件: Bezafibrate,
Ursodeoxycholic acid (UDCA)		2件: Ursodiol ,
Bezafibrate 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
4Standard OF care: udca----1件: 93 💬
5Udca1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬5件: 67, 93, 94, 97, 296 💬
6Ursodeoxycholic acid (udca) 500 MG1件: Ursodeoxycholic acid (UDCA)1件: Ursodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 46 💬